Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

sales@dingminpharma.com

86-311-67260775

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Wszystko
  • Wszystko
  • Tytuł
Język

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

 [Hebei,China]

Typ firmy:Producent , Przedsiębiorstwo Handlowe , Dystrybutor / hurtownik

Główne rynki: Ameryka , Azja , Europa Wschodnia , Europa , Europa Północna , Oceania , Pozostałe rynki , Europa Zachodnia , Na calym swiecie , Afryka , Karaiby , Bliski Wschód

Eksporter:81% - 90%

Certs:ISO9001, CCC, FDA, MSDS, FCC, REACH, RoHS

Dom> Blog> Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

September 03, 2019

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis


FOSTER CITY, Calif.--Jul. 19, 2019--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.


Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartiswill receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.


“Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development.


Gilead’s antiviral portfolio includes among the most widely used medicines for the treatment of HIV, hepatitis B and hepatitis C, as well as influenza infection.


Poprzedni
Następny
Skontaktuj się z nami

Author:

Ms. Lily

E-mail:

sales@dingminpharma.com

Phone/WhatsApp:

+8615933619867

Wszystkie produkty
Aktualności Company
Partia na koniec roku Pharnex w Shijiazhuang

July 03, 2023

Aktualności Industry
FDA zatwierdza nowe leki na chorobę Parkinsona

July 03, 2023

APATINIB PD-1 Wiadomości

July 03, 2023

Blog News
Azazacitidine was first marketed, only 5.6% lower than the original research

December 20, 2019

Pharmaceutical intermediate manufacture APIs Merchants in China

February 21, 2019

You may also like
Related Categories

Wyślij je do tym dostawcy

Przedmiot:
Email:
wiadomość:

Your message must be betwwen 20-8000 characters

Skontaktuj się z nami

Author:

Ms. Lily

E-mail:

sales@dingminpharma.com

Phone/WhatsApp:

+8615933619867

Wszystkie produkty
Aktualności Company
Partia na koniec roku Pharnex w Shijiazhuang

July 03, 2023

Aktualności Industry
FDA zatwierdza nowe leki na chorobę Parkinsona

July 03, 2023

APATINIB PD-1 Wiadomości

July 03, 2023

Blog News
Azazacitidine was first marketed, only 5.6% lower than the original research

December 20, 2019

Pharmaceutical intermediate manufacture APIs Merchants in China

February 21, 2019

Dom

Product

Phone

O nas

Zapytanie
Please Leave Us A Message

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Prześlij załącznik
Wysłać